1993 Volume 86 Issue 7 Pages 1053-1059
The empirical use of FMOX was evaluated in 210 patients with bacterial infections in the otorhinolaryngological field. As a general rule, FMOX 2 or 4 g in adult and 60-150 mg/kg in children was administrated intravenously twice a day. The clinical effectiveness was evaluated by the doctor in charge as excellent, effective, slightly effective or ineffectve. The clinical efficacy was defined as the number of patients excellent or effective responses. The clinical efficacy could be analyzed and in 191 patients and the side effects in
210 patients.
1. The overall clinical efficacy rate was 90.1%; 80.0% in otitis media, 91.7% in paranasal sinusitis, 94.4% in tonsillitis and 91.7% in pharyngitis and laryngitis.
2. The rate of bacterial elimination was 76.2% in 130 patients with positive cultures.
3. Side effects were observed in 8 patients (3.3%) but they were transient ; one had vomiting and the others mild hepatic or renal dysfunction.
We conclude that FMOX is reliable as an empirical treatment of otorhinolaryngological infections.
